Tachmed recognised for innovative approach to Life Sciences by OBN Awards 2025
Pioneering MedTech company, Tachmed, has been recognised for its innovative approach to life sciences by the prestigious OBN Awards, having been shortlisted as a finalist for Best Established Medtech Company 2025.
Co-Founded by Paul Christie and Lord Maxwell Beaverbrook in 2018, Tachmed is reimagining the world of diagnostics through the development of a low-cost, AI-powered device that enables users to self-test for a range of conditions — anytime, anywhere.
Set to officially launch to market in early 2026, TachShield will enable people to easily identify a range of conditions in a matter of seconds, from chronic illnesses such as cardio, obesity and other inflammatory illness biomarkers to infectious diseases such as dengue, flu, Covid-19 and other viruses.
Costing less than lab-based diagnostics, TachShield not only meets the UN’s sustainability goals for 2030 but also boasts the very real potential to transform healthcare systems worldwide.
Now in its 17th year, the OBN Awards are a highly regarded and sought-after programme for the Life Sciences industry, designed to celebrate innovation and outstanding achievement across all corners of the sector.
Set to celebrate finalists across 12 different categories, the OBN Awards shine a light on companies at all stages of development, recognising inspirational leadership, exciting innovation, novel and exciting approaches to unmet clinical needs, outstanding company progression and the delivery of real-life, tangible results.
Discussing this latest accolade, Paul Christie, CEO of Tachmed, said: “To be recognised by the OBN Awards as a finalist for Best Established Medtech Company is a true honour and one that reinforces the importance of our mission to transform the future of healthcare by ensuring everyone has an equal opportunity to manage their health and reduce incidents of serious disease.
We now look forward to meeting like-minded peers at the awards ceremony this November and wish all other finalists the best of luck.”
Lord Maxwell Beaverbrook added: “Tachmed is an impressive and pioneering MedTech business that genuinely does have the potential to revolutionise the global healthcare industry through the capability of TachShield. To be recognised by the OBN Awards for its development at such an early stage is a testament to our team’s innovation and we now look forward to sharing it with the world when we launch to market early next year.”
The OBN Awards 2025 will take place via a dedicated ceremony at the Royal Lancaster Hotel, London on 26th November 2025.
Headquartered in London, Tachmed’s advanced smart health platform will have the capability to significantly reduce healthcare waiting lists, while saving vital costs, resource and even lives through early diagnosis.
For more information, visit:
